For more information please visit: www.alphalabs.co.uk/NABCT Maintain draw-time EV concentration When samples were collected into NABCT, draw-time EV concentration was maintained for up to 7 days at ambient temperature storage. In contrast, EV concentrations increased markedly at days 3 and 7 for equivalent samples collected in EDTA (Figure 3). Maintain draw-time cfRNA concentration To qualitatively compare cfRNA between samples collected in EDTA or NA-BCT, the Bioanalyzer RNA Pico Assay was used per kit included instructions (Agilent). Samples collected into the Nucleic Acid BCT maintained cfRNA concentration for up to 7 days, whereas cfRNA levels increased substantially with time for samples collected into EDTA (Figure 4). Further, samples collected in the Nucleic Acid BCT maintained a drawtime cfRNA size profile for up to 7 days of ambient temperature storage. These data demonstrate that Nucleic Acid BCTs effectively maintain draw-time cfRNA concentration during blood sample storage. Streck Nucleic Acid BCT stabilises all plasma nucleic acids (cfDNA and cfRNA) and extracellular vesicles for up to 7 days at room temperature. This tube is ideal for labs seeking to reduce haemolysis in their samples, maximise plasma yield, and maintain draw-time concentrations of cfDNA, extracellular vesicles, and cfRNA. NA-BCT is a powerful addition to the liquid biopsy toolkit allowing for combined interrogation of both cfDNA (mutation profiling) and cfRNA (transcriptome analysis and expressed fusion gene detection) in addition to downstream analysis of EVs. However, the advantages extend far beyond precise data. NA-BCT liberates laboratories from cold storage constraints, slashing shipping and handling costs. It is perfect for groups relying on offsite laboratories, it extends storage time without compromising analysis. Moreover, it amplifies laboratory efficiency, allowing batches of samples to be processed weekly, contrasting with the immediate attention demanded by traditional tubes. References Nicholas George, Ph.D., Lisa Bartron, MB(ASCP), and Jordan LaRue Nucleic Acid BCT™ maintains draw-time concentration of cell-free DNA, extracellular vesicles, and associated cell-free RNA www.streck.com/wp-content/uploads/2023/06/880237-NABCT-TechNote.pdf Figure 2. Plasma cfDNA levels are stabilised by Nucleic Acid BCT™ for up to 7 days of ambient storage. (A) Workflow of cfDNA collection and analysis. Cellfree DNA isolated from plasma was assayed for concentration, size and purity using a combination of Qubit™ dsDNA HS Assay, Cell-Free DNA ScreenTape analysis, and Bio-Rad ddPCR. Cell-free DNA concentration (B), size (C), and purity (D) in plasma collected into EDTA or Nucleic Acid BCT™ immediately after draw (Draw) or after 3 (Day-3) or 7 days (Day-7) of ambient temperature storage. [DNA] and %cfDNA are graphed as mean ± STDEV for 6 donors. The single donor electropherogram shown in (C) is representative of what is normally observed for all donors. Figure 3. Concentration of EVs from plasma collected into EDTA or Nucleic Acid BCT immediately after draw (Draw) or after 3 (Day-3) or 7 days (Day-7) of ambient temperature storage. n=6 self-declared healthy donors. Figure 4. cfRNA concentration in plasma collected into EDTA or NA-BCT immediately after draw (Draw) or after 3 (Day-3) or 7 days (D ay-7) of ambient temperature storage. www.alphalabs.co.uk © 2024 Copyright Alpha Laboratories Ltd. 13
RkJQdWJsaXNoZXIy MTUyODc1Mw==